Metabolism of ADB‐FUBIATA in zebrafish and pooled human liver microsomes investigated by liquid chromatography–high‐resolution mass spectrometry

Abstract

RationaleADB‐FUBIATA is one of the most recently identified new psychoactive substance (NPS) of synthetic cannabinoids. The co‐use of in vitro (human liver microsomes) and in vivo (zebrafish) models offers abundant metabolites and may give a deep insight into the metabolism of NPS.MethodsIn vivo and in vitro metabolic studies of new synthetic cannabinoid ADB‐FUBIATA were carried out using zebrafish and pooled human liver microsome models. Metabilites were structurally characterized by liquid chromatography–high‐resolution mass spectrometry.ResultsIn total, 18 metabolites were discovered and identified in the pooled human liver microsomes and zebrafish, including seventeen phase I metabolites and one phase II metabolite. The main metabolic pathways of ADB‐FUBIATA were hydroxylation, dehydrogenation, N‐dealkylation, amide hydrolysis, glucuronidation, and combination thereof.ConclusionHydroxylated metabolites can be recommended as metabolic markers for ADB‐FUBIATA because of the structural characteristics and high intensity. These metabolism characteristics of ADB‐FUBIATA were useful for its further forensic or clinical related investigations.